Sharon Shacham, Karyopharm Therapeutics Inc. (KPTI)’s insider Unloaded 10,000 Shares; 4 Bullish Analysts Covering Unilever PLC (UL)

Among 12 analysts covering Unilever (NYSE:UL), 4 have Buy rating, 2 Sell and 6 Hold. Therefore 33% are positive. Unilever had 15 analyst reports since July 24, 2015 according to SRatingsIntel. The stock of Unilever PLC (NYSE:UL) earned “Sector Perform” rating by RBC Capital Markets on Friday, July 22. The rating was initiated by Argus Research on Friday, November 17 with “Hold”. On Tuesday, December 13 the stock rating was upgraded by Jefferies to “Buy”. The firm earned “Neutral” rating on Wednesday, August 12 by Goldman Sachs. As per Monday, August 22, the company rating was initiated by Bernstein. The rating was upgraded by JP Morgan on Tuesday, January 12 to “Overweight”. Barclays Capital downgraded Unilever PLC (NYSE:UL) on Monday, January 23 to “Equal-Weight” rating. The stock has “Buy” rating by Canaccord Genuity on Friday, July 24. The rating was downgraded by ABN Amro to “Sell” on Monday, April 3. Macquarie Research initiated Unilever PLC (NYSE:UL) on Friday, March 17 with “Outperform” rating. See Unilever PLC (NYSE:UL) latest ratings:

17/11/2017 Broker: Argus Research Rating: Hold Initiate
10/08/2017 Broker: RBC Capital Markets Rating: Sell Downgrade

The President & CSO of Karyopharm Therapeutics Inc, Sharon Shacham, has just unloaded – 10,000 shares of the corporation she’s leading and operating – coming to a cumulative transaction value of $125,048 US Dollars (this based on average share price of $12.5). In the last month, she also unloaded 20,000 shares with a total value of about $201,651 USD. The regulatory filing shows that Sharon Shacham now has ownership of roughly 2.67% of the Massachusetts-based company’s market cap This deal was completed on February 08, 2018. A public form filed with the Washington-based Security and Exchange Commission and accessible for free here, discloses full details of the deal.

The stock decreased 1.62% or $0.87 during the last trading session, reaching $52.75. About 1.42M shares traded or 2.88% up from the average. Unilever PLC (NYSE:UL) has risen 20.68% since February 9, 2017 and is uptrending. It has outperformed by 3.98% the S&P500.

Unilever PLC operates in the fast-moving consumer goods market. The company has market cap of $137.63 billion. The firm operates through Personal Care, Foods, Home Care, and Refreshment divisions. It has a 20.97 P/E ratio. The Personal Care segment offers skincare and haircare products, deodorants, and oral care products.

The stock increased 4.35% or $0.57 during the last trading session, reaching $13.68. About 361,944 shares traded or 97.33% up from the average. Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has risen 21.19% since February 9, 2017 and is uptrending. It has outperformed by 4.49% the S&P500.

Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. The company has market cap of $677.61 million. The Company’s lead drug candidate is Selinexor, which is in Phase IIb clinical trial for patients with heavily pretreated multiple myeloma; Phase Ib/II clinical study in combination with backbone treatments for relapsed/refractory multiple myeloma; Phase II/III clinical trial for patients with relapsed and/or refractory multiple myeloma; Phase II clinical study to treat acute myeloid leukemia; Phase IIb clinical trial for patients with diffuse large B-cell lymphoma; and Phase II/III clinical trial to treat liposarcoma. It currently has negative earnings. The firm is also developing KPT-8602 that is in Phase I/II study for patients with relapsed/refractory multiple myeloma; KPT-9274, which is in Phase I clinical trial for patients with advanced solid malignancies or non-HodgkinÂ’s lymphoma; KPT-335, which is in Phase I clinical trial for the treatment of viral indications; and KPT-350 that is in preclinical stage to treat neurological disorders, and inflammatory and autoimmune diseases.

Since August 29, 2017, it had 0 insider buys, and 13 insider sales for $983,230 activity. 10,000 shares were sold by Shacham Sharon, worth $91,553. $1,298 worth of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) was sold by Mirza Mansoor Raza. Primiano Christopher Brett had sold 1,500 shares worth $18,000. $100,769 worth of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) was sold by Kauffman Michael on Monday, January 8.

Analysts await Karyopharm Therapeutics Inc. (NASDAQ:KPTI) to report earnings on March, 15. They expect $-0.58 EPS, up 10.77% or $0.07 from last year’s $-0.65 per share. After $-0.65 actual EPS reported by Karyopharm Therapeutics Inc. for the previous quarter, Wall Street now forecasts -10.77% EPS growth.

Free Email Newsletter

Enter your email address below to get the latest news and analysts’ ratings for your stocks with our free daily email newsletter: